Preclinical discovery of ixabepilone, a highly active antineoplastic agent - Wikidata - awgldk - TriplyDB

Preclinical discovery of ixabepilone, a highly active antineoplastic agent

Preclinical discovery of ixabepilone, a highly active antineoplastic agent

http://www.wikidata.org/entity/Q28272975

about

Cancer wars: natural products strike back Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies.Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane Build/couple/pair strategy for the synthesis of stereochemically diverse macrolactams via head-to-tail cyclization.Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.Biological activity of 4-substituted methoxybenzoyl-aryl-thiazole: an active microtubule inhibitor Novel microtubule-targeting agents - the epothilones.Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence.A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas Identification of glycan structure alterations on cell membrane proteins in desoxyepothilone B resistant leukemia cells.Endometrial carcinoma: a review of chemotherapy, drug resistance, and the search for new agents The epothilones: new therapeutic agents for castration-resistant prostate cancer.Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products A phase 2 trial of ixabepilone plus cetuximab in first-line treatment of metastatic pancreatic cancer A Highly Stereoselective, Efficient, and Scalable Synthesis of the C(1)-C(9) Fragment of the Epothilones.Nerve growth factor alters microtubule targeting agent-induced neurotransmitter release but not MTA-induced neurite retraction in sensory neurons.Novel nitrogen-enriched oridonin analogues with thiazole-fused A-ring: protecting group-free synthesis, enhanced anticancer profile, and improved aqueous solubility Improved synthesis of 6-epi-dictyostatin and antitumor efficacy in mice bearing MDA-MB231 human breast cancer xenografts.Ixabepilone as monotherapy or in combination for the treatment of advanced breast cancer.Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin.The modification of natural products for medical use.Treatment of metastatic breast cancer: second line and beyond.Ixabepilone for the treatment of breast cancer.Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: what next?Medical therapy of endometrial cancer: current status and promising novel treatments.Tubulin: an example of targeted chemotherapy.Recent progress with microtubule stabilizers: new compounds, binding modes and cellular activities.Ixabepilone for the treatment of endometrial cancer.Macrolactam analogues of macrolide natural products.The structural modification of natural products for novel drug discovery.Synthesis and biological evaluation of a potent salicylihalamide A lactam analogue.Axonal Transport Impairment in Chemotherapy-Induced Peripheral Neuropathy Habitat-specific type I polyketide synthases in soils and street sediments.Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer.Remote, Late-Stage Oxidation of Aliphatic C-H Bonds in Amide-Containing Molecules.Synthesis and Evaluation of a Linkable Functional Group-Equipped Analogue of the Epothilones.

P2860

Q26850074-F5385419-B610-4BEA-8366-9893F08E9207 Q33762423-9D3241A9-1EF1-49BD-B6B9-046DCD655FE8 Q33990883-AF4146DD-6155-40A7-A980-FC15BBF35162 Q34130007-A398FD54-3332-48DD-A03A-544ABD11662C Q34204598-DB520466-C851-4084-A8F4-8E8903F516B3 Q34576078-766B60C0-3773-450E-8B7D-91B3DE71EB7A Q34611212-BE97B2F8-89A9-4E62-8367-F880B938E149 Q35076330-235231D3-849D-4CEB-AF55-4904AAB21D67 Q35096335-D893A853-CF02-4A6C-8FDC-7E6798B2262A Q35579621-55248B5C-0F8C-4C96-A4D6-4A0248C1415C Q35583750-54786810-6097-41A4-BEC4-72FA5EB6AE8F Q35584399-09579044-C19E-4A40-AD63-19990B595CF7 Q36273796-5E02A3A4-48D7-48B8-A81D-CC20E3B3D62B Q36347267-F6EEFE10-E90D-49BB-B476-2A97B85CA1D7 Q36738059-D5D0942C-B1BA-426E-83CE-3F21DD798F91 Q36884527-A49F50EA-8015-4B01-BDA0-49E4C6A40F6D Q37017307-B1FF94C9-EBC0-4365-8C09-700DEE38A382 Q37064051-2D30443C-FC2C-4424-9153-A2184E6E802B Q37356274-50DB1390-80BE-49BF-8A36-1E90C6C09CA9 Q37570220-965FAB06-5778-4ECE-A8E7-B810B6735E8B Q37689655-D7AF1937-9629-4C16-B879-E83E8F5D7CC6 Q37802108-2A70E67C-4F31-4CC6-B577-F73E67899079 Q37876407-B8B6E93B-87DF-4CD1-A0F1-6AC54150D828 Q37948672-84B80611-64EA-4970-8F49-07AC0267B91D Q37996079-621DED41-28DA-4C7B-9544-10982D7CF0EA Q38086872-8785FF6E-1A1B-4515-9349-CBE2FF5D58C1 Q38183686-D2E88739-0A51-43B8-8AB8-691C17A9A5E9 Q38763500-1930CB64-3950-45F2-99B6-E7298F125D13 Q38998257-E0E5CE4B-B468-44DA-B233-59C99E801BC6 Q39050184-61A37F90-2007-4A83-AA77-3BEBB38AA06D Q39281821-E25CA5B4-B5EA-48DC-B581-529484B0F7C4 Q42361415-77095E31-6103-42A4-81C8-243AF5B1EF75 Q46487760-2B4C8A27-6192-441C-AA43-9C81028B4707 Q47568290-8DCF8211-222A-4CC4-8E4F-3773DA448642 Q48330898-9F43E99D-7696-44B4-929B-40A78B3975A4 Q48713016-CCBDE7D1-BFF4-43DA-B89E-6E9388F937B2

P2860

Preclinical discovery of ixabepilone, a highly active antineoplastic agent

http://www.wikidata.org/entity/Q28272975

description

2008 nî lūn-bûn

@nan

2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Preclinical discovery of ixabepilone, a highly active antineoplastic agent

@ast

Preclinical discovery of ixabepilone, a highly active antineoplastic agent

@en

Preclinical discovery of ixabepilone, a highly active antineoplastic agent

@nl

type

label

Preclinical discovery of ixabepilone, a highly active antineoplastic agent

@ast

Preclinical discovery of ixabepilone, a highly active antineoplastic agent

@en

Preclinical discovery of ixabepilone, a highly active antineoplastic agent

@nl

prefLabel

Preclinical discovery of ixabepilone, a highly active antineoplastic agent

@ast

Preclinical discovery of ixabepilone, a highly active antineoplastic agent

@en

Preclinical discovery of ixabepilone, a highly active antineoplastic agent

@nl

P1433

Q28272975-4621A13E-8BB9-47FC-85C0-F79FA9F151D1

P1476

Q28272975-B0D0D385-3EA2-42D9-AC59-F4A2FFA03472

P2093

Q28272975-1F81CAE8-79D4-4A0A-B3DA-1A338D38DFAB

Q28272975-32B9DA93-AFCA-40F9-BBE6-75D0AF713A71

Q28272975-4BF7135D-70F7-453B-B8D0-B2C0B6FEB1BF

Q28272975-8F47CF3D-3619-4FEC-B291-B87BA3686B5C

Q28272975-CB4A0C10-51F6-4235-92F0-FEA870ABFBD7

Q28272975-DBCE0812-4981-4DBB-B1B0-E46EC517B776

Q28272975-F0A51BA3-D64D-4671-B2D8-61283B150E7A

P2860

Q28272975-47377F07-C73D-468F-B83A-E2210984DB72

Q28272975-6DC03344-78C3-4446-83F9-244267B364AC

P2888

Q28272975-9A6DAE13-8031-4F79-A695-EE05D590FE8E

P304

Q28272975-5D42194E-DB5D-42E9-AEA7-BB0C62EE462F

P31

Q28272975-2D4BCEF6-C6B1-446F-AE45-FDF6E589426E

P356

Q28272975-B99BD4ED-67CD-4EB1-8966-D6424B38119D

P407

Q28272975-6E1E0F76-505A-4D24-A91C-97D604232C62

P433

Q28272975-8DC58687-7FAE-4030-9E16-3AEE7ED3D67C

P478

Q28272975-B6B589C5-A25B-474D-A9B5-5BF4D0A36E82

P577

Q28272975-8A741B1D-63EB-4316-B363-2AE8E24C3003

P5875

Q28272975-CCF04FCC-1B4D-4B9A-9CAB-00D141090CDA

P6179

Q28272975-59A4816A-2F6B-43CD-97B3-79F804D94426

P698

Q28272975-A57A0E4B-D5A9-4474-B8E3-B6235E0E2DA0

P356

S00280-008-0724-8

P1433

Cancer Chemotherapy and Pharmacology

P1476

Preclinical discovery of ixabepilone, a highly active antineoplastic agent

@en

P2093

Amrita Kamath

http://www.w3.org/2001/XMLSchema#string

Craig R Fairchild

http://www.w3.org/2001/XMLSchema#string

Francis Y F Lee

http://www.w3.org/2001/XMLSchema#string

Gregory Vite

http://www.w3.org/2001/XMLSchema#string

Richard Smykla

http://www.w3.org/2001/XMLSchema#string

Robert Borzilleri

http://www.w3.org/2001/XMLSchema#string

Robert Kramer

http://www.w3.org/2001/XMLSchema#string

P2860

Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells

A generalized Wilcoxon test for comparing arbitrarily singly-censored samples

P2888

s00280-008-0724-8

P304

157-66

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-008-0724-8

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

63

http://www.w3.org/2001/XMLSchema#string

P577

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5504244

http://www.w3.org/2001/XMLSchema#string

P6179

1023608242

http://www.w3.org/2001/XMLSchema#string

P698

18347795

http://www.w3.org/2001/XMLSchema#string